Abstract
Reduced-intensity stem cell transplantation (RIST) has opened a new era for hematopoietic stem cell transplantation (HSCT). It was developed based on the knowledge that graft-versus-tumor (GVT) effect is the main anti-tumor effect in allogeneic HSCT. Because RIST is associated with less morbidity and mortality, it can be applied to many patients who could not undergo conventional HSCT. Experiences in the last decade clarified many issues related to RIST. For example, graft-versus-host disease (GVHD) in RIST may differ in character compared to conventional HSCT. Also, it is now known that intensity of conditioning is important in disease control, and the optimal regimens may be different for each disease or for each disease status. There are still many unsolved questions, and large prospective randomized trials are necessary to resolve these.
Keywords: Reduced-intensity stem cell transplantation, graft-versus-host disease, graft-versus-leukemia effect, mixed chimerism, regimen-related toxicity
Current Stem Cell Research & Therapy
Title: Reduced-Intensity Stem Cell Transplantation for Hematological Malignancies: Current Status and the Future
Volume: 2 Issue: 2
Author(s): Koji Kato, Yasser Khaled and Shin Mineishi
Affiliation:
Keywords: Reduced-intensity stem cell transplantation, graft-versus-host disease, graft-versus-leukemia effect, mixed chimerism, regimen-related toxicity
Abstract: Reduced-intensity stem cell transplantation (RIST) has opened a new era for hematopoietic stem cell transplantation (HSCT). It was developed based on the knowledge that graft-versus-tumor (GVT) effect is the main anti-tumor effect in allogeneic HSCT. Because RIST is associated with less morbidity and mortality, it can be applied to many patients who could not undergo conventional HSCT. Experiences in the last decade clarified many issues related to RIST. For example, graft-versus-host disease (GVHD) in RIST may differ in character compared to conventional HSCT. Also, it is now known that intensity of conditioning is important in disease control, and the optimal regimens may be different for each disease or for each disease status. There are still many unsolved questions, and large prospective randomized trials are necessary to resolve these.
Export Options
About this article
Cite this article as:
Kato Koji, Khaled Yasser and Mineishi Shin, Reduced-Intensity Stem Cell Transplantation for Hematological Malignancies: Current Status and the Future, Current Stem Cell Research & Therapy 2007; 2 (2) . https://dx.doi.org/10.2174/157488807780599248
DOI https://dx.doi.org/10.2174/157488807780599248 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapeutic Use of Brentuximab Vedotin in CD30+ Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Perspectives for cN-II in Cancer.
Current Medicinal Chemistry Current Status of Thalidomide and CC-5013 in the Treatment of Metastatic Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Imatinib Dosing in Gastrointestinal Stromal Tumors (GISTs): When, How Much, and How Long?
Current Clinical Pharmacology Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Current Status and Future Perspectives in the Development of Novel Irreversible Inhibitors for the Treatment of Mutant Non-small Cell Lung Cancer
Current Pharmaceutical Design Cell Cycle and Energy Metabolism in Tumor Cells: Strategies for Drug Therapy
Recent Patents on Anti-Cancer Drug Discovery Equipping CAR-Modified T Cells with a Brake to Prevent Chronic Adverse Effects
Current Gene Therapy Perinatal Gene Transfer to the Liver
Current Pharmaceutical Design Targeting miR-21 Induces Autophagy and Chemosensitivity of Leukemia Cells
Current Drug Targets In-silico Evidences of Regulatory Roles of WT1 Transcription Factor Binding Sites on the Intervening Sequences of the Human Bcl-2 Gene
Current Bioinformatics Iron Chelators: Development of Novel Compounds with High and Selective Anti-Tumour Activity
Current Drug Delivery Evidences and Opinions for Adjuvant Therapy in Pancreatic Cancer
Current Drug Targets Molecular Targeting of Protein Kinases to Optimize Selectivity and Resistance Profiles of Kinase Inhibitors
Current Topics in Medicinal Chemistry Anti-Apoptotic Genes in the Survival of Monocytic Cells During Infection
Current Genomics Clinical Trial Update and Novel Therapeutic Approaches for Metastatic Prostate Cancer
Current Medicinal Chemistry Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry Mechanisms of ERK1/2 Regulation by Seven-Transmembrane-Domain Receptors
Current Pharmaceutical Design Functional Role of miR-34 Family in Human Cancer
Current Drug Targets Hematological Targets of Radiation Damage
Current Drug Targets Pharmacogenomics in Colorectal Cancer
Current Pharmacogenomics